ResultsIQ

ResultsIQ › Latest results › Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited Q4 FY26 results deck summary

NSE: EMCURE · BSE: 544210

Results deck of 12 Jun 2026, summarised by AI from the filing.

FY26 revenue ₹9,204 cr (+16.6%), EBITDA ₹1,789 cr (+21.8%), PAT ₹941 cr (+33.1%), with international revenue ₹5,177 cr (+22.2%).

Key takeaways

  1. FY26 revenue Revenue from operations ₹9,204 cr in FY26 (FY25: ₹7,896 cr, +16.6%), with Q4FY26 revenue ₹2,470 cr (Q4FY25: ₹2,116 cr, +16.7%).
  2. FY26 EBITDA EBITDA ₹1,789 cr in FY26 (FY25: ₹1,469 cr, +21.8%); EBITDA margin 19.4% (FY25: 18.6%, +83 bps).
  3. FY26 PAT PAT ₹941 cr in FY26 (FY25: ₹707 cr, +33.1%); PAT margin 10.2% (FY25: 9.0%, +127 bps).
  4. International growth International revenue ₹5,177 cr in FY26 (FY25: ₹4,236 cr, +22.2%), led by market share gains and new launches.
  5. Domestic growth Domestic revenue ₹4,027 cr in FY26 (FY25: ₹3,660 cr, +10.0%), in line with IPM led by Cardiac, CNS, and oncology therapies.

Original filing on BSE

Emcure Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹2,580 cr (+23% year on year), EBITDA ₹533 cr (+28% year on year), PAT ₹292 cr (+36% year on year), EBITDA margin 20.6% (+79 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹2,470 cr (+17% year on year), EBITDA ₹480 cr (+19% year on year), PAT ₹244 cr (+24% year on year), EBITDA margin 19.4% (+37 bps). Score 63 of 100, In line with trend. EBITDA margin rose 37 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.7% in 30 days (Nifty 500: −1.5%).
  • Q3 FY26: Revenue ₹2,363 cr (+20% year on year), EBITDA ₹493 cr (+39% year on year), PAT ₹231 cr (+53% year on year), EBITDA margin 20.9% (+276 bps). Score 82 of 100, Above trend. EBITDA margin rose 276 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −6.0% in 30 days (Nifty 500: −4.1%).
  • Q2 FY26: Revenue ₹2,270 cr (+13% year on year), EBITDA ₹476 cr (+25% year on year), PAT ₹251 cr (+24% year on year), EBITDA margin 21.0% (+199 bps). Score 66 of 100, Above trend. EBITDA margin rose 199 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −1.2% in 30 days (Nifty 500: −0.2%).
  • Q1 FY26: Revenue ₹2,101 cr (+16% year on year), EBITDA ₹417 cr (+24% year on year), PAT ₹215 cr (+41% year on year), EBITDA margin 19.9% (+128 bps). Score 70 of 100, Above trend. EBITDA margin rose 128 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −3.5% in 29 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹2,116 cr, EBITDA ₹403 cr, PAT ₹197 cr, EBITDA margin 19.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹2,116 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +22.2% in 29 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹1,963 cr, EBITDA ₹355 cr, PAT ₹156 cr, EBITDA margin 18.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,963 cr). Scored once a year-earlier consolidated quarter exists.
  • Q2 FY25: Revenue ₹2,002 cr, EBITDA ₹380 cr, PAT ₹202 cr, EBITDA margin 19.0%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹2,002 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Emcure Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.